Amy Mahery - Roivant Sciences Chief Officer

ROIV Stock  USD 12.53  0.71  6.01%   

Executive

Amy Mahery is Chief Officer of Roivant Sciences
Age 47
Address 50 Broadway, London, United Kingdom, SW1H 0DB
Phone44 20 7400 3347
Webhttps://roivant.com

Roivant Sciences Management Efficiency

The company has return on total asset (ROA) of (0.1844) % which means that it has lost $0.1844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.2896 %, meaning that it created $1.2896 on every $100 dollars invested by stockholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.64 in 2024. Return On Capital Employed is likely to climb to 0.64 in 2024. At this time, Roivant Sciences' Asset Turnover is fairly stable compared to the past year.
Roivant Sciences currently holds 499.75 M in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the company is not taking enough advantage from borrowing. Roivant Sciences has a current ratio of 6.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Roivant Sciences' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Carlo TanziSeres Therapeutics
N/A
Caroline HoldaSeres Therapeutics
N/A
Kim FoxMilestone Pharmaceuticals
N/A
David EgeSeres Therapeutics
49
John PharmDScpharmaceuticals
N/A
SPHR SHRMSCPSeres Therapeutics
52
Alpa ParikhLumos Pharma
N/A
Lee FlowersHCW Biologics
78
Nicole EsqHCW Biologics
N/A
RPh YoungSeres Therapeutics
57
Steve ParsonsScpharmaceuticals
N/A
Eddie MBALumos Pharma
N/A
Rachael NokesScpharmaceuticals
49
Lisa MDSeres Therapeutics
65
MD MBAEliem Therapeutics
50
JD EsqSeres Therapeutics
69
Michael HassmanScpharmaceuticals
N/A
Jeffrey NelsonMilestone Pharmaceuticals
43
Valerie MorissetEliem Therapeutics
54
MD FAAPLumos Pharma
N/A
Nishi MDEliem Therapeutics
N/A
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom. Roivant Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 863 people. Roivant Sciences (ROIV) is traded on NASDAQ Exchange in USA. It is located in 50 Broadway, London, United Kingdom, SW1H 0DB and employs 908 people. Roivant Sciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Roivant Sciences Leadership Team

Elected by the shareholders, the Roivant Sciences' board of directors comprises two types of representatives: Roivant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roivant. The board's role is to monitor Roivant Sciences' management team and ensure that shareholders' interests are well served. Roivant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roivant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Amy Mahery, Chief Officer
Matthew Gline, CEO Director
Marianne Romeo, Head Management
Huafeng Xu, Chief Officer
Josh Chen, General Counsel
Matt Maisak, Chief Platforms
Vivek Ramaswamy, Founder Chairman
Alex Gasner, Executive Health
Jo Chen, General Counsel
PharmD MD, President COO
Drew Kramer, Chief Officer
Kelly Graff, Head People
Richard Pulik, Chief Officer
Deya MD, Chief OfficerInResidence
Srini Ramanathan, Chief Officer
Rakhi Kumar, Chief Officer
Josh JD, General Counsel
Mayukh MD, Chief President
David MD, Chief Dermavant

Roivant Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Roivant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Roivant Stock Analysis

When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.